Harvard Bioscience price target lowered to $3 from $4.50 at Benchmark

TipRanks

Wed, May 14, 2025, 6:14 AM 1 min read

Benchmark lowered the firm’s price target connected Harvard Bioscience (HBIO) to $3 from $4.50 and keeps a Speculative Buy standing connected the shares. The outlook for end-user markets successful biomedical probe continues to beryllium challenging owed to uncertainty astir China tariffs, NIH funding, and biopharmaceutical probe activity, which leads the steadfast to little its 2025 gross estimation arsenic a result. However, contempt the near-term uncertainty, absorption remains optimistic astir the 2025 prospects for recently launched products, says the analyst, who believes shares could acquisition aggregate enlargement if the institution continues to execute its program to turn the concern organically, summation currency flow, and wage down debt.

• Quickly and easy unpack a company's show with TipRanks' caller KPI Data for astute concern decisions

• Receive undervalued, marketplace resilient stocks consecutive to you inbox with TipRanks' Smart Value Newsletter

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See Insiders’ Hot Stocks connected TipRanks >>

Read More connected HBIO:

Disclaimer & DisclosureReport an Issue

• Blade Air Mobility Reports Q1 2025 Financial Results

• Harvard Bioscience Earnings Call: Mixed Sentiments and Strategic Moves

• Harvard Bioscience reports Q1 adjusted EPS (1c) vs. 2c past year

• Harvard Bioscience sees Q2 gross $18M-$20M

• HBIO Earnings Report this Week: Is It a Buy, Ahead of Earnings?